Amgen to Report 2Q 2025 Financial Results and Host Conference Call

Amgen will report its Q2 2025 financial results on August 5, 2025, after the US financial markets close. The announcement will be followed by a conference call with the investment community at 4:30 pm ET. Amgen's chairman and CEO, Robert A. Bradway, and other senior management members will participate in the call. The webcast will be available on Amgen's website and will be archived for 90 days after the event.

Amgen Inc. (AMGN) is set to release its second-quarter (Q2) 2025 financial results on August 5, 2025, after the U.S. financial markets close. The announcement will be followed by a conference call with the investment community at 4:30 pm ET. Amgen's chairman and CEO, Robert A. Bradway, and other senior management members will participate in the call. The webcast will be available on Amgen's website and will be archived for 90 days after the event.

Analysts predict that Amgen will report quarterly earnings of $5.25 per share, representing a 5.6% increase compared to the same period last year. Revenues are forecasted to be $8.86 billion, a year-over-year increase of 5.6% [2]. The consensus EPS estimate for the quarter has been adjusted downward by 0.2% over the past 30 days, reflecting analysts' reassessment of their initial projections.

Key product sales metrics are expected to show mixed results. Revenue from product sales is forecasted to be $8.49 billion, a 5.6% increase year-over-year. Sales of Neulasta are expected to decline by 12.3% to $92.14 million, while sales of LUMAKRAS/LUMYKRAS are projected to increase by 7.3% to $91.20 million. Otezla sales are expected to decrease by 1.9% to $533.54 million. Neulasta sales in the ROW are forecasted to decline by 22.3% to $23.31 million, while Neulasta sales in the U.S. are expected to decrease by 10.8% to $66.88 million. Vectibix sales in the ROW are projected to decrease by 1% to $135.60 million, while Vectibix sales in the U.S. are expected to increase by 6.7% to $141.96 million. Enbrel sales in the U.S. are forecasted to decline by 12.9% to $786.00 million [2].

Amgen's earnings surprise history shows that the company has consistently beaten estimates in the trailing four quarters, with an average earnings surprise of 8.34% [1]. The company's stock has risen 18.4% so far this year compared to a 1.9% increase for the industry.

Investors will be closely watching Amgen's second-quarter results for updates on key pipeline candidates, such as MariTide, a GIPR/GLP-1 receptor for obesity. Additionally, the impact of biosimilars on sales of established products and the company's operating margin will be closely scrutinized.

References:
[1] https://www.nasdaq.com/articles/amgen-gears-report-q2-earnings-will-beat-streak-continue
[2] https://www.nasdaq.com/articles/gear-amgen-amgn-q2-earnings-wall-street-estimates-key-metrics